Table 3. Antibiotic resistance of G− B bacteria (strains, n).
| Antibiotics | Escherichia coli | P | Klebsiella pneumoniae | P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Community-acquired (n = 83) | Nosocomial (n = 70) | Community-acquired (n = 40) | Nosocomial (n = 35) | |||||||
| ESBL positive (n = 39) | ESBL negative (n = 44) | ESBL positive (n = 46) | ESBL negative (n = 24) | ESBL positive (n = 15) | ESBL negative (n = 25) | ESBL positive (n = 10) | ESBL negative (n = 25) | |||
| Ampicillin | 35 | 29 | 46 | 16 | 0.06 | 11 | 24 | 10 | 23 | 0.31 |
| Piperacillin | 28 | 17 | 37 | 12 | <0.01 | 11 | 13 | 10 | 6 | 0.22 |
| Ticarcillin/clavulanic acid | 37 | 15 | 44 | 9 | 0.08 | 9 | 10 | 7 | 12 | 0.56 |
| Piperacillin/tazobactam | 12 | 6 | 8 | 1 | 0.15 | 1 | 1 | 4 | 0 | 0.31 |
| Cefoperazone | 38 | 3 | 37 | 3 | 0.34 | 5 | 1 | 10 | 1 | 0.09 |
| Cefoperazone/Sulbactam | 10 | 1 | 11 | 2 | 0.37 | 2 | 0 | 3 | 1 | 0.31 |
| Ceftazidime | 32 | 2 | 30 | 1 | 0.68 | 9 | 0 | 10 | 0 | 0.55 |
| Ceftriaxone | 38 | 2 | 45 | 2 | 0.02 | 11 | 0 | 10 | 0 | 0.92 |
| Cefepime | 26 | 2 | 29 | 3 | 0.33 | 0 | 0 | 6 | 1 | <0.01 |
| Cefmetazole | 8 | 4 | 4 | 6 | 0.98 | 9 | 0 | 2 | 3 | 0.36 |
| Aztreonam | 35 | 2 | 33 | 1 | 0.62 | 11 | 0 | 8 | 1 | 0.86 |
| Imipenem | 1 | 0 | 2 | 0 | 0.46 | 0 | 0 | 1 | 0 | 0.28 |
| Meropenem | 1 | 0 | 1 | 0 | 0.90 | 0 | 0 | 1 | 0 | 0.28 |
| Amikacin | 5 | 1 | 4 | 1 | 0.98 | 1 | 1 | 3 | 1 | 0.31 |
| Levofloxacin | 30 | 10 | 31 | 10 | 0.20 | 9 | 1 | 4 | 4 | 0.83 |
| SMZ | 29 | 12 | 35 | 22 | <0.01 | 9 | 2 | 7 | 4 | 0.71 |
| Fosfomycin | 11 | 2 | 3 | 3 | 0.18 | 2 | 7 | 3 | 2 | 0.36 |